Ozempic Patent Expiration Leads to Affordable Generics in India

Novo Nordisk's semaglutide, branded as Ozempic, is going off patent, allowing Indian manufacturers to produce generics. The generic versions are expected to cost around $14 in India. This shift may significantly reduce costs for millions of consumers globally, as these generics become available. The absence of such generics in the US market due to patent protection highlights potential disparities in drug pricing between countries. The move could influence weight-loss drug markets and alter competitive dynamics.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.